Approved indications
Dysport is approved for intramuscular treatment of cervical dystonia in adults, temporary improvement of moderate to severe glabellar frown lines in adults younger than 65 years, and treatment of upper and lower limb spasticity in adults and in children 2 years of age and older.

Common off‑label uses
• Aesthetic: treatment of other facial expression lines such as horizontal forehead lines, lateral canthal lines (crow’s feet), and some lower‑face wrinkles.
• Therapeutic: selected other focal dystonias, spasticity patterns not specifically studied in the label, and in some practices conditions like sialorrhea or hyperhidrosis.
Evidence for these uses comes mainly from small randomized and open‑label studies plus clinical experience, so dosing and outcomes are less standardized than for approved indications.

Efficacy expectations
• Improvement in symptoms or wrinkles usually begins within 2–7 days, with maximal effect around 2 weeks for glabellar lines and within about 1–4 weeks for cervical dystonia and limb spasticity.
• Benefits generally last about 3–4 months for glabellar lines and about 12–16 weeks or longer for cervical dystonia and spasticity, after which repeat injections are considered (no sooner than every 12 weeks in adults and typically 12–16 weeks or more in children, depending on the limb and response).
• Overall, Dysport’s efficacy for its approved neurologic and aesthetic indications is broadly comparable to other botulinum toxin type A products when appropriate dose conversions and injection techniques are used, with some patients perceiving modest differences in spread or duration between brands.

Typical dosing by indication
• Cervical dystonia (adults): commonly starts at 500 Units intramuscularly divided among affected neck muscles, with adjustments in 250‑Unit steps to a usual range of 500–1000 Units per treatment session.
• Limb spasticity (adults): 500–1000 Units for upper limb and 1000–1500 Units for lower limb per session, with a maximum combined dose of 1500 Units across all limbs at a given treatment visit.
• Limb spasticity (children ≥2 years): weight‑based dosing of about 8–16 Units/kg per affected upper limb and 10–15 Units/kg per affected lower limb, with a maximum of 30 Units/kg or 1000 Units in any treatment session, whichever is lower.
• Glabellar lines (adults <65 years): a total of 50 Units divided into five intramuscular injections of 10 Units each across the procerus and corrugator muscles.

How injections are given
• Dysport is supplied as a lyophilized powder that is reconstituted with preservative‑free 0.9% sodium chloride and injected directly into selected muscles using a fine needle, often with guidance such as electromyography or ultrasound for spasticity and cervical dystonia.
• It is administered during an office or clinic visit, not taken by mouth; food intake and time of day do not meaningfully affect its action.
• Dysport potency units are unique to this product and must not be converted 1:1 from other botulinum toxin preparations.

Retreatment intervals and special instructions
• In adults, retreatment for cervical dystonia and limb spasticity is based on clinical need but should not occur more often than every 12 weeks; glabellar‑line treatments are also typically spaced at least 3 months apart.
• In children with limb spasticity, minimum retreatment intervals are generally 16 weeks for upper limbs and at least 12 weeks (often 16–22 weeks) for lower limbs, with actual timing guided by duration of benefit and safety.
• Before each new cycle, dosing and muscle selection are individualized based on response to prior injections, current pattern of spasticity or dystonia, and any adverse effects.

Missed appointment and overdose
• If a scheduled injection visit is missed, patients should contact the clinic to reschedule rather than receiving injections earlier than recommended; sessions should still respect the minimum interval between treatments.
• Overdose or accidental administration of excessive units may cause profound muscle weakness, serious swallowing or breathing problems, or generalized botulism‑like symptoms, and requires urgent medical evaluation, supportive care, and contact with emergency services or a poison control center.

Common side effects
• Spasticity treatment: in adults, muscle weakness in the injected limb, pain in arms or legs, and falls; in children, upper respiratory tract infection, sore throat, runny or stuffy nose, cough, and fever.
• Cervical dystonia: neck muscle weakness or pain, difficulty swallowing, dry mouth, tiredness, voice changes, and injection‑site pain or discomfort.
• Glabellar lines: nose and throat irritation, headache, injection‑site pain or skin reactions, eyelid swelling, drooping eyelid (ptosis), sinus irritation, and nausea.
These effects usually occur within days to a few weeks after injection, are dose‑ and site‑related, and are generally mild to moderate and reversible.

Serious or rare adverse effects
• Distant spread of toxin can rarely cause botulism‑like symptoms such as severe generalized weakness, double or blurred vision, drooping eyelids, trouble speaking clearly, loss of bladder control, or difficulty breathing or swallowing, which may be life‑threatening and require emergency care.
• Severe allergic reactions (including anaphylaxis, widespread hives, swelling of the face or throat, or sudden trouble breathing) are uncommon but require immediate medical attention.
• Marked or prolonged difficulty swallowing can lead to aspiration, pneumonia, weight loss, or need for tube feeding, especially in patients with underlying neurologic disease or bulbar weakness.

Warnings and precautions
• Dysport is not approved for children under 2 years; glabellar‑line treatment has been adequately studied only in adults younger than 65 years.
• Extra caution is needed in people with neuromuscular junction disorders (e.g., myasthenia gravis, Lambert‑Eaton syndrome), motor neuron disease (e.g., ALS), significant respiratory compromise, or baseline swallowing problems, because they are at higher risk for severe weakness and breathing or swallowing difficulties.
• In pregnancy and breastfeeding, human data are limited; use is generally avoided—especially for cosmetic indications—unless the potential benefit clearly outweighs potential risks.
• Units of Dysport are not interchangeable with units of other botulinum toxin products, so doses must be specifically calculated for this brand to avoid under‑ or overdosing.

Overall safety and reporting
• When administered by trained clinicians at recommended doses and intervals, Dysport has a long safety record and most side effects are manageable and temporary, although the boxed warning about distant spread of toxin applies as for all botulinum toxins.
• Suspected side effects can be reported to the FDA MedWatch program (online or at 1‑800‑FDA‑1088) and to the manufacturer, and patients can review the Medication Guide and FDA drug safety communications for updated safety information.

Medication and supplement interactions
• Concomitant use of other botulinum toxin products (e.g., Botox, Myobloc, Xeomin) can enhance toxin effects and side effects and generally should be avoided or very carefully coordinated.
• Drugs that impair neuromuscular transmission—such as aminoglycoside or polymyxin antibiotics, certain magnesium salts, some muscle relaxants, and inhaled or intravenous anesthetics—may increase the risk of excessive weakness and respiratory compromise when used around the time of Dysport injections.
• Sedating medicines (sleep aids, some antihistamines, opioids, benzodiazepines) and alcohol can worsen drowsiness or diminish protective reflexes in patients who experience swallowing or breathing problems after Dysport treatment.
• No specific food restrictions are required, and most vitamins and common supplements are unlikely to alter Dysport’s effect, but all prescription, OTC, and herbal products should be reviewed with the treating clinician.

Conditions and co‑medications requiring extra caution
• Pre‑existing neuromuscular junction disorders, peripheral neuropathies, motor neuron disease, or significant baseline respiratory or bulbar weakness increase vulnerability to serious dysphagia and breathing difficulties.
• Bleeding disorders or use of anticoagulants and antiplatelet agents can increase bruising or bleeding at injection sites and may require timing adjustments or specific injection techniques.
• Prior surgery, trauma, or extensive scar tissue in the planned injection area can alter anatomy and may necessitate imaging‑guided injection or dose modification.

Monitoring and follow‑up
• Routine blood tests or ECGs are not usually required, but patients should be monitored clinically for new or worsening muscle weakness, difficulty swallowing, breathing problems, or vision changes in the hours to weeks after injection.
• Children with severe spasticity, patients with neuromuscular disease, and anyone with compromised respiratory or swallowing function may need closer observation after each treatment.
• Any unexpected, severe, or persistent adverse effect should prompt urgent evaluation and may lead to changes in future dosing, injection sites, or the decision to continue Dysport therapy.

Q: What is Dysport and what conditions is it used to treat?
A: Dysport is an injectable botulinum toxin type A medicine that relaxes overactive muscles; in the United States it is approved for cervical dystonia in adults, moderate to severe glabellar frown lines in adults younger than 65 years, and limb spasticity in adults and in children 2 years of age and older.

Q: How long do Dysport results usually last?
A: Most people notice improvement within a few days, with effects that typically last about 3–4 months for glabellar lines and around 3–4 months or longer for cervical dystonia and limb spasticity before another treatment may be needed.

Q: How often can I receive Dysport injections?
A: In adults, treatments for cervical dystonia and spasticity are generally spaced at least 12 weeks apart and cosmetic glabellar‑line treatments at least every 3 months, with timing based on how long your benefit lasts and your overall safety profile.

Q: Who should not receive Dysport?
A: People who are allergic to any botulinum toxin or to cow’s milk protein, have an infection at the planned injection site, or have had a serious reaction to a botulinum toxin product in the past should not receive Dysport, and those with significant neuromuscular, breathing, or swallowing problems require special caution and individual risk–benefit assessment.

Q: Can I keep taking my regular medicines while being treated with Dysport?
A: Many medicines can be continued, but you should tell your clinician about all prescription and nonprescription drugs and supplements you use, because some—such as certain injected antibiotics, muscle relaxants, sedatives, or other botulinum toxin products—can increase the risk of excessive weakness or breathing problems when combined with Dysport.

Storage
• Patients usually do not store Dysport at home; unopened vials are kept by healthcare providers refrigerated at 2–8°C (36–46°F), protected from light, and not used after the expiration date.
• After the powder is mixed with saline, the reconstituted solution is kept in the refrigerator, protected from light, used within 24 hours, and not frozen.

Handling and disposal
• Needles, syringes, and vials are disposed of by the clinic as medical sharps and biohazard waste, not in household trash or recycling.
• If you are given any supplies for home use, follow the written storage and sharps‑disposal instructions provided and keep all materials out of reach of children and pets.